Literature DB >> 29471023

Evidence of clinical response and stability of Ceftolozane/Tazobactam used to treat a carbapenem-resistant Pseudomonas Aeruginosa lung abscess on an outpatient antimicrobial program.

A Stewart1, J A Roberts2, S C Wallis3, A M Allworth4, A Legg5, K L McCarthy6.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29471023     DOI： 10.1016/j.ijantimicag.2018.02.008

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN： 0924-8579            Impact factor:   5.283


× No keyword cloud information.
  4 in total

1.  Ceftolozane-tazobactam in an elastomeric infusion device for ambulatory care: an in vitro stability study.

Authors:  Edward Raby; Saiyuri Naicker; Fekade Bruck Sime; Laurens Manning; Steven C Wallis; Saurabh Pandey; Jason A Roberts
Journal:  Eur J Hosp Pharm       Date:  2019-12-16

2.  Real-world use of ceftolozane/tazobactam: a systematic literature review.

Authors:  Laura Puzniak; Ryan Dillon; Thomas Palmer; Hannah Collings; Ashley Enstone
Journal:  Antimicrob Resist Infect Control       Date:  2021-04-08       Impact factor: 4.887

Review 3.  Systematic Literature Review of Real-world Evidence of Ceftolozane/Tazobactam for the Treatment of Respiratory Infections.

Authors:  Laura Puzniak; Ryan Dillon; Thomas Palmer; Hannah Collings; Ashley Enstone
Journal:  Infect Dis Ther       Date:  2021-07-18

4.  Clinical and Safety Evaluation of Continuously Infused Ceftolozane/Tazobactam in the Outpatient Setting.

Authors:  Bruce M Jones; Kathryn Huelfer; Christopher M Bland
Journal:  Open Forum Infect Dis       Date:  2020-01-12       Impact factor: 3.835
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.